365 related articles for article (PubMed ID: 28139313)
1. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.
Weinacht KG; Charbonnier LM; Alroqi F; Plant A; Qiao Q; Wu H; Ma C; Torgerson TR; Rosenzweig SD; Fleisher TA; Notarangelo LD; Hanson IC; Forbes LR; Chatila TA
J Allergy Clin Immunol; 2017 May; 139(5):1629-1640.e2. PubMed ID: 28139313
[TBL] [Abstract][Full Text] [Related]
2. Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.
Bloomfield M; Kanderová V; Paračková Z; Vrabcová P; Svatoň M; Froňková E; Fejtková M; Zachová R; Rataj M; Zentsová I; Milota T; Klocperk A; Kalina T; Šedivá A
J Clin Immunol; 2018 Jul; 38(5):589-601. PubMed ID: 29934865
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation.
Moriya K; Suzuki T; Uchida N; Nakano T; Katayama S; Irie M; Rikiishi T; Niizuma H; Okada S; Imai K; Sasahara Y; Kure S
Int J Hematol; 2020 Aug; 112(2):258-262. PubMed ID: 32180118
[TBL] [Abstract][Full Text] [Related]
4. Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
Kayaoglu B; Kasap N; Yilmaz NS; Charbonnier LM; Geckin B; Akcay A; Eltan SB; Ozturk G; Ozen A; Karakoc-Aydiner E; Chatila TA; Gursel M; Baris S
J Clin Immunol; 2021 May; 41(4):769-779. PubMed ID: 33475942
[TBL] [Abstract][Full Text] [Related]
5. Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1.
Baris S; Alroqi F; Kiykim A; Karakoc-Aydiner E; Ogulur I; Ozen A; Charbonnier LM; Bakır M; Boztug K; Chatila TA; Barlan IB
J Clin Immunol; 2016 Oct; 36(7):641-8. PubMed ID: 27379765
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.
Vargas-Hernández A; Mace EM; Zimmerman O; Zerbe CS; Freeman AF; Rosenzweig S; Leiding JW; Torgerson T; Altman MC; Schussler E; Cunningham-Rundles C; Chinn IK; Carisey AF; Hanson IC; Rider NL; Holland SM; Orange JS; Forbes LR
J Allergy Clin Immunol; 2018 Jun; 141(6):2142-2155.e5. PubMed ID: 29111217
[TBL] [Abstract][Full Text] [Related]
7. Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib.
Dotta L; Todaro F; Baronio M; Giacomelli M; Pinelli M; Giambarda M; Brognoli B; Greco S; Rota F; Cortesi M; Soresina A; Moratto D; Tomasi C; Ferraro RM; Giliani S; Badolato R
J Clin Immunol; 2024 Apr; 44(4):85. PubMed ID: 38578354
[TBL] [Abstract][Full Text] [Related]
8. Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.
Tabellini G; Vairo D; Scomodon O; Tamassia N; Ferraro RM; Patrizi O; Gasperini S; Soresina A; Giardino G; Pignata C; Lougaris V; Plebani A; Dotta L; Cassatella MA; Parolini S; Badolato R
J Allergy Clin Immunol; 2017 Aug; 140(2):553-564.e4. PubMed ID: 28069426
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC).
Zheng J; van de Veerdonk FL; Crossland KL; Smeekens SP; Chan CM; Al Shehri T; Abinun M; Gennery AR; Mann J; Lendrem DW; Netea MG; Rowan AD; Lilic D
Eur J Immunol; 2015 Oct; 45(10):2834-46. PubMed ID: 26255980
[TBL] [Abstract][Full Text] [Related]
10. The human Stat1 gain-of-function T385M mutation causes expansion of activated T-follicular helper/T-helper 1-like CD4 T cells and sex-biased autoimmunity in specific pathogen-free mice.
Scott O; Visuvanathan S; Reddy E; Mahamed D; Gu B; Roifman CM; Cohn RD; Guidos CJ; Ivakine EA
Front Immunol; 2023; 14():1183273. PubMed ID: 37275873
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitors modulate innate immune responses to micro-organisms relevant to chronic mucocutaneous candidiasis.
Rösler B; Wang X; Keating ST; Joosten LAB; Netea MG; van de Veerdonk FL
Clin Exp Immunol; 2018 Nov; 194(2):205-219. PubMed ID: 30069986
[TBL] [Abstract][Full Text] [Related]
12. Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib.
Al Shehri T; Gilmour K; Gothe F; Loughlin S; Bibi S; Rowan AD; Grainger A; Mohanadas T; Cant AJ; Slatter MA; Hambleton S; Lilic D; Leahy TR
J Clin Immunol; 2019 Nov; 39(8):776-785. PubMed ID: 31512162
[TBL] [Abstract][Full Text] [Related]
13. Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.
Okada S; Asano T; Moriya K; Boisson-Dupuis S; Kobayashi M; Casanova JL; Puel A
J Clin Immunol; 2020 Nov; 40(8):1065-1081. PubMed ID: 32852681
[TBL] [Abstract][Full Text] [Related]
14. Case report: A STAT1 gain-of-function mutation causes a syndrome of combined immunodeficiency, autoimmunity and pure red cell aplasia.
Xie Y; Shao F; Lei J; Huang N; Fan Z; Yu H
Front Immunol; 2022; 13():928213. PubMed ID: 36105803
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Stem Cell Transplantation in Patients with Heterozygous STAT1 Gain-of-Function Mutation.
Kiykim A; Charbonnier LM; Akcay A; Karakoc-Aydiner E; Ozen A; Ozturk G; Chatila TA; Baris S
J Clin Immunol; 2019 Jan; 39(1):37-44. PubMed ID: 30543054
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for chronic mucocutaneous candidiasis.
van de Veerdonk FL; Netea MG
J Infect; 2016 Jul; 72 Suppl():S56-60. PubMed ID: 27161991
[TBL] [Abstract][Full Text] [Related]
17. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody.
Yamazaki Y; Yamada M; Kawai T; Morio T; Onodera M; Ueki M; Watanabe N; Takada H; Takezaki S; Chida N; Kobayashi I; Ariga T
J Immunol; 2014 Nov; 193(10):4880-7. PubMed ID: 25288569
[TBL] [Abstract][Full Text] [Related]
18. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation.
Higgins E; Al Shehri T; McAleer MA; Conlon N; Feighery C; Lilic D; Irvine AD
J Allergy Clin Immunol; 2015 Feb; 135(2):551-3. PubMed ID: 25662309
[No Abstract] [Full Text] [Related]
19. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis.
van de Veerdonk FL; Plantinga TS; Hoischen A; Smeekens SP; Joosten LA; Gilissen C; Arts P; Rosentul DC; Carmichael AJ; Smits-van der Graaf CA; Kullberg BJ; van der Meer JW; Lilic D; Veltman JA; Netea MG
N Engl J Med; 2011 Jul; 365(1):54-61. PubMed ID: 21714643
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations.
Leiding JW; Okada S; Hagin D; Abinun M; Shcherbina A; Balashov DN; Kim VHD; Ovadia A; Guthery SL; Pulsipher M; Lilic D; Devlin LA; Christie S; Depner M; Fuchs S; van Royen-Kerkhof A; Lindemans C; Petrovic A; Sullivan KE; Bunin N; Kilic SS; Arpaci F; Calle-Martin O; Martinez-Martinez L; Aldave JC; Kobayashi M; Ohkawa T; Imai K; Iguchi A; Roifman CM; Gennery AR; Slatter M; Ochs HD; Morio T; Torgerson TR;
J Allergy Clin Immunol; 2018 Feb; 141(2):704-717.e5. PubMed ID: 28601685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
